ライフサイエンスコーパス: translocator protein

1 a specific PET ligand for the assessment of translocator protein.

2 exoprotein and a cognate TpsB outer membrane translocator protein.

3 AhR-hsp90, AhR-XAP2, and/or AhR-AhR nuclear translocator protein.

4 acking the aryl hydrocarbon receptor nuclear translocator protein.

5 ween pRb and the AhR but not the AhR nuclear translocator protein.

6 de (DPA-714) is a radioligand for the 18-kDa translocator protein.

7 1 polymorphism in the gene encoding the 18Kd translocator protein.

8 ceptor and aryl hydrocarbon receptor nuclear translocator proteins.

9 Typhimurium chaperone and translocator proteins.

10 ur understanding of biological mechanisms of translocator protein 18 (TSPO) function but also indicat

11 ation is associated with increased levels of translocator protein 18 kDa (TSPO) and binding sites for

12 (PET) imaging with radiotracers that target translocator protein 18 kDa (TSPO) has become a popular

13 ssion tomography (PET) studies targeting the translocator protein 18 kDa (TSPO) have been limited by

14 In AD, the translocator protein 18 kDa (TSPO) is overexpressed in t

15 d can be monitored through expression of the translocator protein 18 kDa (TSPO) on activated microgli

16 PET imaging of translocator protein 18 kDa (TSPO) permits longitudinal,

17 Translocator protein 18 kDa (TSPO) PET is a widely evalu

18 Most studies investigated the translocator protein 18 kDa (TSPO) using PET; neuroimmun

19 ET imaging of brown adipose tissue (BAT) and translocator protein 18 kDa (TSPO) via a combination of

20 Translocator protein 18 kDa (TSPO), a biomarker of neuro

21 To measure translocator protein 18 kDa (TSPO), a marker of activate

22 ro evaluated for their potential to bind the translocator protein 18 kDa (TSPO), a protein today reco

23 ssion tomography with (11)C-PBR28 to measure translocator protein 18 kDa (TSPO), a putative biomarker

24 with 14- to 17-fold higher sensitivity than translocator protein 18 kDa (TSPO)-PET imaging, the esta

25 ton, Finn, et al. used [(11)C]ER176, a novel translocator protein 18 kDa (TSPO)-positron emission tom

26 BR28 binds to the high-affinity state of the translocator protein 18 kDa (TSPO).

27 lial hyperactivity, marked by an increase in translocator protein 18 kDa (TSPO).

28 hat has been imaged extensively using PET is translocator protein 18 kDa (TSPO).

29 Translocator protein 18 kDa [TSPO or peripheral-type ben

30 of an emerging radiotracer for imaging brain translocator protein 18 kDa, namely [(11)C]ER176.

31 in 18 (TSPO) function but also indicate that translocator protein 18 may be a promising therapeutic t

32 AC-5216, XBD-173), a synthetic ligand of the translocator protein 18, ameliorates degeneration of dop

33 ive effects were evident as well using GE180 translocator protein 18-kDa (TSPO) imaging with positron

34 The PET radioligand (11)C-PBR28 targets translocator protein (18 kDa) (TSPO) and is a potential

35 As a PET biomarker for inflammation, translocator protein (18 kDa) (TSPO) can be measured wit

36 The translocator protein (18 kDa) (TSPO) is described as a b

37 some BDZs also bind mitochondrial receptors [translocator protein (18 kDa) (TSPO)] and promote the sy

38 Translocator protein (18 kDa), known as TSPO, is a recog

39 Translocator protein (18 kDa, TSPO), previously known as

40 The mitochondrial translocator protein (18 kDa; TSPO) is a high-affinity c

41 The translocator protein (18 kDa; TSPO), previously known as

42 Brain translocator protein 18k Da (TSPO) binding, a putative m

43 racer [(11)C]PBR28, which targets the 18-kDa translocator protein, a marker sensitive to immune chall

44 (PET) radiotracer [11C]PBR28, which binds to translocator protein, a molecular marker that is up-regu

45 phy/magnetic resonance imaging data of 18kDa translocator protein (an inflammatory marker) in MWA pat

46 s: Period, Aryl hydrocarbon receptor nuclear translocator protein and Single-minded) domain of the di

47 at is consistent with the biodistribution of translocator protein and yields a dose burden that is co

48 cterial cells HrpJ controls the secretion of translocator proteins and inside plant cells it suppress

49 structure and topology of the outer membrane translocator proteins and the large exoproteins that the

50 Last, we identified and validated TSPO (translocator protein) and S100A12 (S100 calcium-binding

51 Prior to pore formation, the translocator proteins are bound to a small chaperone wit

52 iple systems indicates that the pore-forming translocator proteins are exported before effectors, but

53 T3SS translocator proteins are required for effector proteins

54 These translocator proteins are stabilized in the cytoplasm an

55 following the binding of the AhR/AhR nuclear translocator protein (ARNT) heterodimer to dioxin respon

56 (AHR) and aryl hydrocarbon receptor nuclear translocator protein (ARNT) were coexpressed in the yeas

57 ex prior to association with the AhR nuclear translocator protein (ARNT).

58 e form of a heterodimer with the AHR nuclear translocator protein (ARNT).

59 This is the first demonstration of a translocator protein being stably associated with the TT

60 the healthy volunteers, suggesting increased translocator protein binding (z > 4.72).

61 n patients, and could explain the overlap in translocator protein binding values between patients wit

62 We found higher translocator protein-binding in slow decliners than fast

63 here when PET imaging was performed with the translocator protein-binding radioligand (18)F-GE180.

64 Amyloidosis controls displayed higher translocator protein-binding than controls, especially i

65 f interest and voxel-wise comparison, 18-kDa translocator protein-binding was higher in high affinity

66 Translocator protein-binding was measured using a simple

67 Translocator protein-binding was positively correlated w

68 as to test for an association between 18 kDa translocator protein brain positron emission tomography

69 get of neuroinflammation using PET is 18-kDa translocator protein, but its limitations have spurred t

70 e secretion channel because the pore-forming translocator proteins can still be secreted while effect

71 on channel protein or the adenine nucleotide translocator protein could not be demonstrated by immuno

72 ovide new insights into interactions between translocator proteins critical for virulence.

73 Translocator protein density increases when microglia ar

74 Translocator protein density measured by distribution vo

75 ecretion system, or with mutants lacking the translocator proteins, do not develop clinical disease,

76 interaction between EspD and the hydrophilic translocator protein EspA.

77 EspA filaments are homo-polymers made of the translocator protein EspA.

78 the needle that is composed of the secreted translocator protein EspA.

79 hogenic E. coli is unique in that one of the translocator proteins, EspA, polymerizes to form an exte

80 intimin receptor (Tir) and EspF, and for the translocator proteins EspB and EspD.

81 ar within the EPEC LEE region: CesD, for the translocator proteins EspB and EspD; CesT, for the effec

82 N terminus of the type III secretion system translocator proteins EspB, EspD, and EspA mediate prote

83 The PET tracer 11C-PK11195 targets the translocator protein expressed by activated microglia an

84 carbon receptor and aryl hydrocarbon nuclear translocator protein expression are not responsible for

85 healthy control participants also underwent translocator protein fluorine 18 ((18)F)-DPA-714 PET for

86 Translocator protein genotyping allowed the classificati

87 fying the increased expression of the 18-kDa translocator protein have been developed.

88 lter nuclear AhR levels or hAhR/hAhR nuclear translocator protein heterodimer DRE-binding activity as

89 recently showed microglia involvement using translocator protein imaging.

90 Translocator protein immunostaining was detected on meni

91 The reduction of (11)C-PBR28 binding to translocator protein in the brain of patients with Parki

92 m Salmonella and is therefore likely to be a translocator protein in the type-III secretion system of

93 ion of the aryl hydrocarbon receptor nuclear translocator protein in vivo by adenovirus-mediated RNA

94 es pilus protein and no longer secretes four translocator proteins in culture, and it fails to inject

95 Translocator proteins include two hydrophobic proteins,

96 slocation to the nucleus, or AhR-AhR nuclear translocator protein interactions.

97 he recruitment and stable association of the translocator protein IpaB at the TTSA needle tip in the

98 tal sensor for triggering recruitment of the translocator protein IpaB to the needle tip.

99 trigger recruitment of the first hydrophobic translocator protein, IpaB, to the tip complex where it

100 The Shigella translocator proteins, IpaB and IpaC, form a pore comple

101 eruginosa, the chaperone of the pore-forming translocator proteins is PcrH.

102 ic members of the Yersinia genus require the translocator protein LcrV for proper function of the typ

103 ibition does not alter hAhR and hAhR nuclear translocator protein levels or TCDD-induced down-regulat

104 functional MRI, in addition to PET with the translocator protein ligand 11C-PBR28.

105 GE180 for imaging activated microglia (18-kD translocator protein ligand [TSPO]) and static 30- to 60

106 microPET imaging of the stable binding of a translocator protein ligand suggested no radiation-speci

107 ement, were examined using a specific 18-kDa translocator protein ligand, (11)C-PBR28, and T1-weighte

108 Translocator protein of 18 kDa (TSPO) is a highly conser

109 ctivity as determined by (18)F-GE-180 18-kDa translocator protein PET (TSPO-PET) in preserved brain r

110 Translocator protein PET and (1)H MR spectroscopy have b

111 e immune cell activation using (18)F-DPA-714 translocator protein PET and to explore the relationship

112 patients underwent 11C-PK11195 mitochondrial translocator protein PET imaging, as an index of microgl

113 Glial activation in white matter assessed by translocator protein PET significantly improves predicti

114 as quantified with 11C-PK11195 mitochondrial translocator protein PET.

115 aging of glia in humans are limited to TSPO (Translocator protein) PET, which is expensive, methodolo

116 The translocator proteins PopB, PopD, and PcrV are secreted

117 Here we used the Pseudomonas aeruginosa translocator protein PopD as a model to identify its exp

118 1-weighted and T2-weighted scans, and 18-kDa translocator protein-positive lesions on PET are promisi

119 Last, using translocator protein positron emission tomography (TSPO-

120 progression using a second-generation 18-kDa translocator protein positron emission tomography radiot

121 whether microglial activity, measured using translocator-protein positron emission tomography (PET)

122 sitron emission tomography scanning with the translocator protein radioligand 11C-PBR28 was performed

123 usly measure microglial activation using the translocator protein radioligand 11C-PK11195, and blood-

124 ivation in patients with MS using the 18-kDa translocator protein radioligand [(18)F]PBR111.

125 YopD, a translocator protein, represses the expression of T3SS g

126 on particle and association with ER membrane translocator protein Sec61.

127 These results showed a positive translocator protein signal throughout the expansive hyp

128 on receptor and the aryl hydrocarbon nuclear translocator protein, suggesting that aryl hydrocarbon r

129 We used translocator protein-targeted molecular imaging to obtai

130 Translocator protein-targeted PET is a reliable tool for

131 pe III secretion systems rely on hydrophobic translocator proteins that form a pore in the host cell

132 To accomplish this, bacteria secrete translocator proteins that form a pore in the host-cell

133 n factor that dimerizes with the AHR nuclear translocator protein to mediate gene regulation.

134 ,5-a]pyrimidine-3-acetamide ((18)F-DPA-714) (translocator protein) to understand the role of GAMMs in

135 Translocator protein total distribution volume (TSPO V(T

136 to compare (18)F-DPA714, a second-generation translocator protein tracer, with (11)C-JNJ717, a novel

137 ata for the structure of the A139T mutant of translocator protein TSPO from Rhodobacter sphaeroides s

138 Translocator protein TSPO is an 18 kDa protein implicate

139 ectional design using (18)F-FDG (n = 43) and translocator protein (TSPO) ((18)F-GE180; n = 58) small-

140 e ((18)F-PBR06) for detecting alterations in translocator protein (TSPO) (18 kDa), a biomarker of mic

141 Translocator protein (TSPO) (18 kDa), a marker of inflam

142 Translocator protein (TSPO) (18 kDa), formerly called th

143 ivated, microglia increase the expression of translocator protein (TSPO) 18 kDa, thereby making the T

144 Here, we demonstrate that the translocator protein (TSPO) and a member of its mitochon

145 the CP-localized expression of mitochondrial translocator protein (TSPO) and CP volume in autistic ad

146 wth, inflammation, and invasion, such as the translocator protein (TSPO) and matrix metalloproteinase

147 In glioblastoma multiforme (GBM), translocator protein (TSPO) and murine double minute (MD

148 althy volunteers, genetically stratified for translocator protein (TSPO) binding status, underwent PE

149 es the first comprehensive quantification of translocator protein (TSPO) binding using SPECT and 6-ch

150 Ligands of the translocator protein (TSPO) elicit pleiotropic neuroprot

151 PET imaging with 18-kDa translocator protein (TSPO) enables longitudinal monitor

152 hy (PET) with a radiotracer sensitive to the translocator protein (TSPO) expressed by activated micro

153 11C-PBR28 PET can detect the 18-kDa translocator protein (TSPO) expressed within macrophages

154 line class was exploited to search for a new translocator protein (TSPO) fluorescent probe endowed wi

155 et al. reported on a crystal structure for a translocator protein (TSPO) from Rhodobacter sphaeroides

156 adiolabeled ligands selective for the 18 kDa translocator protein (TSPO) has become the most widely u

157 nt of neuroinflammation agents targeting the translocator protein (TSPO) has been hindered by a commo

158 The mitochondrial translocator protein (TSPO) has been implicated in CNS d

159 Elevated expression of translocator protein (TSPO) has been shown to predict di

160 The 18-kDa translocator protein (TSPO) has been used in PET as an i

161 ssion tomography (PET) imaging of the 18 kDa translocator protein (TSPO) has been used to investigate

162 While PET imaging of the 18-kDa translocator protein (TSPO) has been widely used to asse

163 PET radioligands targeting the 18-kDa translocator protein (TSPO) have been used as in vivo ma

164 ective of this study was to evaluate whether translocator protein (TSPO) imaging could be used to vis

165 Here we compare translocator protein (TSPO) imaging using 6-chloro-2-(4'

166 argeting the neuroinflammatory marker 18 kDa translocator protein (TSPO) in patient cohorts with depr

167 PET radioligand binding to the 18-kD translocator protein (TSPO) in the brains of patients wi

168 The translocator protein (TSPO) is a commonly used imaging t

169 Increased expression of translocator protein (TSPO) is a feature of microglial a

170 Translocator protein (TSPO) is a key member of the mitoc

171 PET targeting the 18 kDa mitochondrial translocator protein (TSPO) is a molecular-specific appr

172 The human 18 kDa translocator protein (TSPO) is a protein located on the

173 Translocator protein (TSPO) is an 18-kDa cholesterol-bin

174 Translocator protein (TSPO) is expressed at a low level

175 The 18-kDa translocator protein (TSPO) is gaining recognition as a

176 The 18-kDa translocator protein (TSPO) is increasingly recognized a

177 The 18 kDa translocator protein (TSPO) is increasingly used to stud

178 The increased expression of 18 kDa Translocator protein (TSPO) is one of the few available

179 Translocator protein (TSPO) is upregulated in activated

180 The 18-kDa mitochondrial translocator protein (TSPO) is upregulated in high-grade

181 n emission tomography (PET) targeting 18 kDa Translocator Protein (TSPO) is widely used for localisin

182 in-3-yl)-N,N-die thylacetamide (6b), a novel translocator protein (TSPO) ligand exhibiting a 36-fold

183 4-phenylquinazoline-2-carboxamide series of translocator protein (TSPO) ligands have been explored f

184 It remains unclear how different translocator protein (TSPO) ligands reflect the spatial

185 ol-3-ylglyoxylamides as potent and selective translocator protein (TSPO) ligands, two subsets of nove

186 5 PET, which aims to image expression of the translocator protein (TSPO) on activated microglia in th

187 nificant role in Alzheimer disease (AD), and translocator protein (TSPO) PET imaging allows us to qua

188 -L-DOPA, 6-[(18)F]fluoro-m-tyrosine, and the translocator protein (TSPO) PET ligand [(18)F]DAA1106.

189 -G-F) , and APPswe) together with 136 18-kDa translocator protein (TSPO) PET scans for microglial act

190 Several translocator protein (TSPO) PET studies have shown incre

191 Inflammation has been usefully imaged with translocator protein (TSPO) PET, but most inflammation P

192 Since 18-kDa translocator protein (TSPO) plays an important role in r

193 PET imaging of the 18-kDa translocator protein (TSPO) provides a biomarker for mic

194 -in-human prospective study using the 18-kDa translocator protein (TSPO) radioligand 18F-DPA714 for P

195 On the one hand, the translocator protein (TSPO) radioligand N,N-diethyl-2-(2

196 sclerosis (ALS) and can be visualized using translocator protein (TSPO) radioligands.

197 DPA-714), which binds with high affinity the translocator protein (TSPO) receptor, is used as a marke

198 a-isosters of PK11195, the well-known 18 kDa translocator protein (TSPO) reference ligand, and synthe

199 se of SPECT/PET imaging agents targeting the translocator protein (TSPO) that is upregulated on activ

200 This study proposes the 18 kDa Translocator Protein (TSPO) to be one of those.

201 (11)C-PBR28 is a second-generation translocator protein (TSPO) tracer with characteristics

202 es that involved early imaging of the 18 kDa translocator protein (TSPO) using positron emission tomo

203 re, we demonstrate that visualization of the translocator protein (TSPO) with [(18)F]DPA-714-PET-MRI

204 y-3-pyridinyl)acetamide) binds to the 18-kDa translocator protein (TSPO), a biomarker of glia.

205 we investigated the involvement and role of translocator protein (TSPO), a biomarker of microglial a

206 For PET imaging of 18-kDa translocator protein (TSPO), a biomarker of neuroinflamm

207 Ligands of the 18 kDa translocator protein (TSPO), a marker for activated micr

208 on tomography (PET) and radioligands for the translocator protein (TSPO), a marker for glial activati

209 re the binding of [(11)C]PBR28 to the 18 kDa translocator protein (TSPO), a marker for microglial act

210 PBR28, we quantified expression of the 18kDa translocator protein (TSPO), a marker of activated micro

211 PBR28, we show increased brain levels of the translocator protein (TSPO), a marker of glial activatio

212 Brain levels of 18-kDa translocator protein (TSPO), a marker of microglial acti

213 eration tracer for PET imaging of the 18-kDa translocator protein (TSPO), a marker of neuroinflammati

214 ssion Tomography brain imaging of the 18-kDa translocator protein (TSPO), a microglial biomarker, was

215 y was associated with higher availability of translocator protein (TSPO), a microglial marker (B = 4.

216 [(11)C]PBR28 was used to measure the 18-kDa translocator protein (TSPO), a microglial marker, at bas

217 Translocator protein (TSPO), a mitochondrial protein inv

218 inical studies have demonstrated that 18 kDa translocator protein (TSPO), a putative marker of neuroi

219 Translocator protein (TSPO), also referred to as periphe

220 The translocator protein (TSPO), an 18-kDa transmembrane pro

221 easured the in vivo expression of the 18 kDa translocator protein (TSPO), an activated glial marker e

222 ssion tomography (PET) imaging targeting the translocator protein (TSPO), an immune cell marker, we s

223 the brain levels of the glial marker 18 kDa translocator protein (TSPO), and changes in functional c

224 The 18-kDa translocator protein (TSPO), expressed by various cell t

225 l with high affinity and selectivity for the translocator protein (TSPO), expressed on activated glia

226 he most common PET neuroinflammation target, translocator protein (TSPO), has limitations, lacking ce

227 The mitochondrial protein, translocator protein (TSPO), is a widely used biomarker

228 composed of the outer mitochondrial membrane translocator protein (TSPO), previously known as periphe

229 Translocator protein (TSPO), previously known as the per

230 The translocator protein (TSPO), previously known as the per

231 The 18-kilodalton translocator protein (TSPO), proposed to be a key player

232 these deficits via the mitochondrial 18 kDa translocator protein (TSPO), rather than classical gamma

233 the effects of FGIN-1-27 were independent of translocator protein (TSPO), the reported target for thi

234 ssion tomography (PET) imaging of the 18 kDa translocator protein (TSPO), which is upregulated in act

235 formation on immune activation is the 18-kDa translocator protein (TSPO), which is upregulated in act

236 Translocator protein (TSPO), which is upregulated in act

237 pinal cord levels of the glial marker 18-kDa translocator protein (TSPO), which suggests that neuroin

238 ntified alterations in the in vivo levels of translocator protein (TSPO)-a mitochondrial protein-in p

239 ivation can be detected in vivo using 18-kDa translocator protein (TSPO)-binding radioligands and PET

240 R) inhibitor-mediated microglia depletion on translocator protein (TSPO)-dependent neuroinflammation

241 al outcomes in an ischemic mouse model using translocator protein (TSPO)-PET/CT and MR imaging, ex vi

242 oidogenic acute regulatory protein (StAR) or translocator protein (TSPO).

243 tive inflammatory processes by targeting the translocator protein (TSPO).

244 vated expression of the 18 kDa mitochondrial translocator protein (TSPO).

245 binds to the neuroinflammatory marker 18 kDa Translocator Protein (TSPO).

246 evels of the neuroinflammation marker 18 kDa translocator protein (TSPO).

247 binding associated with the 36 kDa dimer of translocator protein (TSPO).

248 mography (PET) radioligands that bind to the translocator protein (TSPO).

249 r developed for SPECT and targets the 18-kDa translocator protein (TSPO).

250 anied by a rapid up-regulation of the 18-kDa translocator protein (TSPO).

251 r gut expression of NADPH oxidase (NOX2) and translocator protein (TSPO).

252 ivo by PET imaging with radioligands for the translocator protein (TSPO, e.g. 11C-PK11195).

253 Function of the mammalian translocator protein (TSPO; previously known as the peri

254 on MRI, 7 Tesla functional MRI, [(11)C]PBR28 translocator protein [TSPO] positron emission tomography

255 endent neuroinflammatory markers (the 18 kDa translocator protein, TSPO, and myoinositol) compared to

256 The 18 kDa translocator protein, TSPO, is a cholesterol-binding pro

257 Translocator proteins (TSPOs) bind steroids and porphyri

258 istribution volume of (11)C-PBR28 binding to translocator protein was significantly reduced compared

259 eletion of Pcsk9) mice, we showed that TSPO (translocator protein) was increased by Pcsk9 deficiency.

260 f (11)C-PBR28 to the microglia marker 18 kDa translocator protein, was examined using positron emissi

261 11)C](R)PK11195-PET measures upregulation of translocator protein, which is associated with microglia

262 of COX-1 and COX-2 are compared with 18-kDa translocator protein, with special consideration of thei

263 The T3SS translocator proteins YopB and YopD form pores in host m

264 Both were able to associate with the translocator protein YopD, and Scc3 expression restored